Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;15(1):21982.
doi: 10.1038/s41598-025-09123-7.

Lipid accumulation product and cardiometabolic index as indicators for sarcopenia: A cross-sectional study from NHANES 2011-2018

Affiliations

Lipid accumulation product and cardiometabolic index as indicators for sarcopenia: A cross-sectional study from NHANES 2011-2018

Xuyan Hu et al. Sci Rep. .

Abstract

Although evidence suggests that lipid accumulation product (LAP) and cardiometabolic index (CMI) may be associated with the pathogenesis of sarcopenia, their relationship remains unclear. This study aims to investigate their association with sarcopenia. This cross-sectional study analyzed data from 4,172 adults aged 20-59 years from the NHANES 2011-2018 cycles. Log-transformed LAP and CMI were the primary exposure variables. Sarcopenia was defined based on the appendicular skeletal muscle mass divided by body mass index (ASM/BMI) according to FNIH guidelines (< 0.789 in males, < 0.512 in females). Weighted analyses examined the associations between LAP, CMI, and sarcopenia. Multivariable logistic regression, restricted cubic spline (RCS), and threshold analysis were used to assess associations, nonlinear patterns, and potential cutoff points. Subgroup analyses explored associations in specific populations. The dataset was randomly split into training (70%) and validation (30%) sets. LASSO regression was applied to identify key associated factors, followed by a nomogram for estimating the probability of sarcopenia. Model performance was evaluated in both the training and validation sets. Sensitivity analyses were performed using untransformed LAP and CMI to assess the robustness of the findings. Ln-transformed LAP (Ln LAP) and Ln-transformed CMI (Ln CMI) were significantly associated with sarcopenia. Threshold effect analysis identified inflection points (Ln LAP: 4.64, Ln CMI: -0.14) beyond which associations weakened. Individuals in the top quartiles of Ln LAP and Ln CMI exhibited significantly higher odds of sarcopenia (Ln LAP: OR = 8.78, 95% CI: 4.92-15.67; Ln CMI: OR = 4.44, 95% CI: 2.41-8.21). Subgroup analyses revealed stronger associations among adults aged 20-29 and 50-59 years, individuals with higher education levels, and drinkers. Classification models with Ln LAP and Ln CMI performed robustly (AUC: 0.780, 0.768) with high accuracy. Sensitivity analyses confirmed consistent nonlinear associations and dose-response relationships for untransformed LAP and CMI. LAP and CMI showed a positive association with sarcopenia in U.S. adults aged 20-59 years. The developed models highlight this relationship, offering potential guidance for identifying and managing high-risk populations.

Keywords: Cardiometabolic index; Cross-sectional studies; Intra-abdominal fat; Lipid accumulation product; Metabolic syndrome; Muscle strength; NHANES; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethics approval: All data involved in this research were collected in accordance with the Declaration of Helsinki and approved by the NCHS Ethics Review Board under Protocol #2011–17 (effective October 26, 2010 through October 26, 2017) and Protocol #2018–01 (effective beginning October 26, 2017) prior to being recorded in the NHANES database.

Figures

Fig. 1
Fig. 1
Participant selection flowchart.
Fig. 2
Fig. 2
RCS analysis demonstrating nonlinear associations of Ln LAP (a) and Ln CMI (b) with sarcopenia.
Fig. 3
Fig. 3
Lasso Regression for key variables: (a) regression coefficient paths. (b) cross-validation plot.
Fig. 4
Fig. 4
Nomogram for predicting sarcopenia: (a) Model with Ln LAP. (b) Model with Ln CMI.
Fig. 5
Fig. 5
Evaluation of classification models on the training set using Ln LAP and Ln CMI: (a) ROC plot. (b) calibration plot. (c) DCA plot.

References

    1. Cruz-Jentoft, A. J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing.48, 601 (2019). - PMC - PubMed
    1. Beaudart, C. et al. Health outcomes of sarcopenia: A consensus report by the outcome working group of the global leadership initiative in sarcopenia (GLIS). Aging Clin. Exp. Res.37(1), 100 (2025). - PMC - PubMed
    1. Petermann-Rocha, F. et al. Global prevalence of sarcopenia and severe sarcopenia: A systematic review and meta-analysis. J. Cachex. Sarcopenia Muscle.13(1), 86–99 (2022). - PMC - PubMed
    1. Yuan, S. & Larsson, S. C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism (Clin. Exp.).144, 155533 (2023). - PubMed
    1. Benz, E. et al. Sarcopenia and sarcopenic obesity and mortality among older people. JAMA Netw. Open.7, e243604 (2024). - PMC - PubMed

Grants and funding

LinkOut - more resources